An interventional study of Biospecimen Collection and FDG-Positron Emission Tomography and Computed Tomography Scan in Thyroid Gland Medullary Carcinoma, sponsored by Jonsson Comprehensive Cancer Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Jonsson Comprehensive Cancer Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Carcinoma, Medullary with a site in United States — 12 open to participants now, 24 under way, 1 of them phase 3. Carcinoma, Medullary · United States.
Among the 81 studies in Carcinoma, Medullary with a site in United States, this one is the 12th largest by planned enrollment of the 66 interventional ones that give a count, is one of 2 that started in 2027, is one of 9 with no phase, reaches primary completion later than 20 of the 22 other live ones, and was the 78th registered.
144 studies on the registry are indexed under Carcinoma, Medullary; 30 are open to participants now.
Browse Carcinoma, Medullary studies →12 of the 81 studies in Carcinoma, Medullary with a site in United States are open now. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Canada, Japan and 1 more country
Ages 18–100
University of Arizona · Sites in United States
Ages 18–99
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 16 Carcinoma, Medullary studies recruiting now, 9 (56%) set no upper age limit and 3 (19%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 35 · Phase 3 4 · Phase 4 1
First in 1996; this study’s year is marked. 2 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 30 across 100 interventional studies indexed under Carcinoma, Medullary.
Median enrollment 30 across the 66 interventional studies, 413 across the 10 observational. Of the 52 that completed or were terminated, 26 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 81 have an industry lead sponsor. The 10 most frequent:
Jonsson Comprehensive Cancer Center is the lead sponsor of 398 studies on the registry; 66 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 2 (5%) have results posted.
Jonsson Comprehensive Cancer Center has 3 studies filed under Carcinoma, Medullary — fewer than ten, so there is no comparison to draw.
4 of the studies in Carcinoma, Medullary with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07259304University of Southern CaliforniaSocial Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors | 2026-12-31 |
| NCT07713901Novo Nordisk A/SDatabase Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma | 2026-12-31 |
| NCT04467021ECOG-ACRIN Cancer Research GroupCancer and Blood Pressure Management, CARISMA Study | 2027-08-31 |
| NCT04759911M.D. Anderson Cancer CenterSelpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 81 studies in Carcinoma, Medullary with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial studies how well thyroid lobectomy with ipsilateral central neck dissection works to treat medullary thyroid cancer (MTC) in patients without a germline RET mutation (sporadic). Currently, sporadic and germline RET (rearranged during transfection) mutation positive MTCs that are limited to the thyroid are managed in the same way, complete surgical removal of the entire thyroid gland (total thyroidectomy) with surgical removal of lymph nodes and other tissues on both sides of the neck (bilateral central neck dissection). Total thyroidectomy and bilateral central neck dissection carry a high risk of complications, and total thyroidectomy requires patients to take lifelong thyroid hormone replacement therapy, which can impact quality of life. Research has shown that patients with sporadic MTC do not have a high risk of developing MTC in the remaining normal thyroid tissue and that they may be able to be managed differently than patients with germline RET mutations. Thyroid lobectomy with ipsilateral central neck dissection is a surgical procedure which removes only the lobe of the thyroid gland that is affected by cancer as well as the lymph nodes and other tissues from the affected side of the neck. Thyroid lobectomy with ipsilateral central neck dissection may be a safer, more tolerable, and/or more effective way to treat sporadic MTC.
PRIMARY OBJECTIVE:
I. To determine the number of patients that have no biochemical evidence of persistent medullary thyroid cancer following thyroid lobectomy and ipsilateral prophylactic central neck dissection alone versus number of patients with biochemical evidence of persistent MTC that requires completion thyroidectomy.
SECONDARY OBJECTIVES:
I. Determine the short-term oncologic treatment outcomes of a novel staged approach to sporadic medullary thyroid cancer, defined by response to therapy category (excellent, biochemical incomplete, structural incomplete).
II. Determine the prevalence of undetected foci of medullary thyroid cancer in contralateral thyroid lobe and contralateral lymph nodes.
OUTLINE:
Patients undergo thyroid lobectomy with unilateral central neck dissection on study. Patients then undergo blood sample collection for calcitonin and carcinoembryonic antigen (CEA) monitoring with neck ultrasound and/or gallium-68 (Ga-68) or fludeoxyglucose F-18 (FDG) positron emission tomography (PET)/computed tomography (CT) at 3 and 6 month follow-ups. Patients with no biochemical or imaging evidence of persistent disease undergo routine cancer surveillance. Patients with either of the following: 1) Elevated or rising calcitonin and/or CEA plus imaging suggestive of residual disease in the contralateral thyroid lobe or contralateral cervical lymph nodes, or 2) Elevated or rising calcitonin and/or CEA with negative imaging for an alternate source, consistent with biochemical evidence of residual disease in the remaining thyroid lobe, may undergo completion thyroidectomy and/or contralateral neck dissection during follow up. Patients also undergo additional blood sample collection, neck ultrasound, and/or Ga-68 or FDG PET/CT throughout the study.
After completion of study intervention, patients are followed up at day 14 and months 3, 6, 12, 18, and 24.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Documentation of a medullary thyroid cancer diagnosis as evidenced by:
Exclusion Criteria:
Indication for total thyroidectomy unrelated to medullary thyroid cancer:
Ultrasound findings consistent with:
Suspicious thyroid nodules > 1 cm that are Thyroid Imaging Reporting and Data Systems 2 (TIRADS2) or higher without fine needle aspiration (FNA)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergo thyroid lobectomy with unilateral central neck dissection on study. Patients then undergo blood sample collection for calcitonin and CEA monitoring with neck ultrasound and/or Ga-68 or FDG PET/CT at 3 and 6 month follow-ups. Patients with no biochemical or imaging evidence of persistent disease undergo routine cancer surveillance. Patients with either of the following: 1) Elevated or rising calcitonin and/or CEA plus imaging suggestive of residual disease in the contralateral thyroid lobe or contralateral cervical lymph nodes, or 2) Elevated or rising calcitonin and/or CEA with negative imaging for an alternate source, consistent with biochemical evidence of residual disease in the remaining thyroid lobe, may undergo completion thyroidectomy and/or contralateral neck dissection during follow up. Patients also undergo additional blood sample collection, neck ultrasound, and/or Ga-68 or FDG PET/CT throughout the study.
Procedure: Biospecimen Collection · Procedure: FDG-Positron Emission Tomography and Computed Tomography Scan · Procedure: Ga-68 PET/CT Scan · Procedure: Neck Dissection · Behavioral: Surveillance · Procedure: Thyroid Lobectomy · Procedure: Thyroidectomy · Procedure: Ultrasound Imaging
Undergo blood sample collection
Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection
Undergo FDG PET/CT
Also known as: FDG PET/CT
Undergo Ga-68 PET/CT
Also known as: Gallium-68 PET/CT Scan, Gallium-68 Positron Emission Tomography and Computed Tomography Scan
Undergo unilateral central neck dissection
Undergo contralateral neck dissection
Undergo routine cancer surveillance
Also known as: Epidemiology / Surveillance
Undergo thyroid lobectomy
Also known as: Lobectomy of Thyroid Gland, Unilateral Thyroid Lobectomy
Undergo completion thyroidectomy
Undergo neck ultrasound
Also known as: 2-Dimensional Grayscale Ultrasound Imaging, 2-Dimensional Ultrasound Imaging, 2D-US, Ultrasonography, Ultrasound, Ultrasound Test, Ultrasound, Medical, US
Proportion of patients who achieve biochemical remission
Will calculate the proportion of patients who achieve biochemical remission at 3 months (normal calcitonin and carcinoembryonic antigen \[CEA\]). Exact 95% confidence intervals will be provided. Exploratory subgroup analyses (e.g., stratified by baseline calcitonin level, tumor size, or nodal status) may be conducted to generate hypotheses but will not be powered for formal inference.
Time frame: Up to 3 months
Proportion of patients requiring completion thyroidectomy
Completion thyroidectomy will be indicated in the setting of: Elevated or rising calcitonin and/or CEA plus imaging (neck ultrasound or positron emission tomography \[PET\]/computed tomography \[CT\]) suggestive of residual disease in the contralateral thyroid lobe or contralateral cervical lymph nodes; or elevated or rising calcitonin and/or CEA with negative neck ultrasound and PET/CT for an alternate source, consistent with biochemical evidence of residual disease in the remaining thyroid lobe. Exact 95% confidence intervals will be provided. Exploratory subgroup analyses (e.g., stratified by baseline calcitonin level, tumor size, or nodal status) may be conducted to generate hypotheses but will not be powered for formal inference.
Time frame: Up to 12 months
Short-term oncologic outcomes
Short-term oncologic outcomes will be categorized according to the American Thyroid Association ATA) "response to therapy" framework, adapted for medullary thyroid carcinoma. Categories will include: Excellent response: Normal calcitonin and CEA with no structural evidence of disease on imaging; Biochemical incomplete response: Abnormal calcitonin and/or CEA without structural evidence of disease; Structural incomplete response: Evidence of structural disease on imaging, regardless of biochemical status. Will be summarized descriptively. Exact 95% confidence intervals will be reported. Comparisons to baseline disease features (e.g., initial calcitonin levels, tumor size, lymph node involvement) may be explored but will be considered hypothesis-generating only.
Time frame: At 12 months
Prevalence of occult contralateral disease
Among patients who undergo completion thyroidectomy and/or contralateral neck dissection, will assess the prevalence of previously undetected foci of medullary thyroid cancer in the contralateral thyroid lobe and contralateral cervical lymph nodes. Pathologic findings will be reported as proportions with corresponding exact 95% confidence intervals.
Time frame: Perioperative/Periprocedural
Start is estimated for Sep 2027; primary completion for Sep 2032, 60 months later.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: start Sep 2026 → Sep 2027, primary completion Sep 2031 → Sep 2032 and completion Apr 2032 → Sep 2033.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jonsson Comprehensive Cancer Center →